Theriva Biologics Inc. (TOVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theriva Biologics Inc. (TOVX) has a cash flow conversion efficiency ratio of -0.159x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.46 Million) by net assets ($15.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Theriva Biologics Inc. (TOVX) total market value for the company's overall valuation and market capitalisation.
Theriva Biologics Inc. - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Theriva Biologics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Theriva Biologics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theriva Biologics Inc. ranked by their cash flow conversion efficiency. Explore TOVX cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Diversified Energy Company PLC
LSE:DEC
|
0.201x |
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
0.008x |
|
Saga plc
LSE:SAGA
|
0.721x |
|
Wise Group AB
ST:WISE
|
0.075x |
|
Ryvyl Inc
NASDAQ:RVYL
|
0.948x |
|
ENTYR Ltd
AU:ETR
|
0.167x |
|
Cyngn Inc
NASDAQ:CYN
|
-0.174x |
|
Origin Agritech Limited
STU:39O1
|
N/A |
Annual Cash Flow Conversion Efficiency for Theriva Biologics Inc. (1993–2025)
The table below shows the annual cash flow conversion efficiency of Theriva Biologics Inc. from 1993 to 2025. View Theriva Biologics Inc. (TOVX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.38 Million | $-16.67 Million | -1.084x | -21.99% |
| 2024-12-31 | $19.07 Million | $-16.94 Million | -0.888x | -85.63% |
| 2023-12-31 | $39.70 Million | $-19.00 Million | -0.479x | -36.83% |
| 2022-12-31 | $54.56 Million | $-19.08 Million | -0.350x | -77.46% |
| 2021-12-31 | $65.41 Million | $-12.89 Million | -0.197x | +91.48% |
| 2020-12-31 | $5.26 Million | $-12.17 Million | -2.314x | -91.62% |
| 2019-12-31 | $11.49 Million | $-13.87 Million | -1.208x | -84.91% |
| 2018-12-31 | $26.45 Million | $-17.28 Million | -0.653x | -111.02% |
| 2017-12-31 | $-3.41 Million | $-20.20 Million | 5.925x | +147.76% |
| 2016-12-31 | $2.25 Million | $-27.90 Million | -12.406x | -378.60% |
| 2015-12-31 | $15.00 Million | $-38.89 Million | -2.592x | -54.06% |
| 2014-12-31 | $9.56 Million | $-16.08 Million | -1.683x | -231.99% |
| 2013-12-31 | $15.23 Million | $-7.72 Million | -0.507x | +25.94% |
| 2012-12-31 | $13.03 Million | $-8.92 Million | -0.684x | -68.03% |
| 2011-12-31 | $7.06 Million | $-2.88 Million | -0.407x | -27.86% |
| 2010-12-31 | $3.58 Million | $-1.14 Million | -0.319x | +61.32% |
| 2009-12-31 | $3.54 Million | $-2.92 Million | -0.824x | -14.83% |
| 2008-12-31 | $6.76 Million | $-4.85 Million | -0.717x | -29.68% |
| 2007-12-31 | $11.95 Million | $-6.61 Million | -0.553x | -175.54% |
| 2006-12-31 | $11.79 Million | $-2.37 Million | -0.201x | -113.06% |
| 2005-12-31 | $-703.84K | $-1.08 Million | 1.537x | +306.12% |
| 2002-12-31 | $-15.39 Million | $-5.82 Million | 0.379x | -57.36% |
| 2001-12-31 | $-9.09 Million | $-8.07 Million | 0.888x | -93.49% |
| 2000-12-31 | $-413.72K | $-5.65 Million | 13.647x | +156.73% |
| 1999-12-31 | $671.07K | $-16.14 Million | -24.056x | +9.95% |
| 1998-12-31 | $700.00K | $-18.70 Million | -26.714x | -977.19% |
| 1997-12-31 | $-2.20 Million | $-6.70 Million | 3.045x | +186.29% |
| 1996-12-31 | $1.70 Million | $-6.00 Million | -3.529x | +15.29% |
| 1995-12-31 | $1.80 Million | $-7.50 Million | -4.167x | -146.30% |
| 1994-12-31 | $-500.00K | $-4.50 Million | 9.000x | +511.43% |
| 1993-12-31 | $1.60 Million | $-3.50 Million | -2.188x | -- |
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcin… Read more